Story perspectives

Trump Secures Lower GLP-1 Prices for Medicare Recipients

11/7/2025

Summary

Story summary

U.S. President Donald Trump announced a deal with Eli Lilly and Novo Nordisk to cut GLP-1 prices for Medicare and Medicaid recipients, effective January 2026.
Co-pays will be capped at $50 per month, with cash prices as low as $299.
The agreement includes tariff relief and fast-track regulatory vouchers for future drugs.
Novo Nordisk plans a $10 billion U.S. investment, and GLP-1 coverage expands to prediabetes and heart patients.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act, enacted on December 8, 2003, introduced Medicare Part D, providing prescription drug coverage to over 39 million beneficiaries. This legislation prohibited Medicare from negotiating drug prices, a point of contention among lawmakers. Recent agreements between President Trump and pharmaceutical companies aim to address these pricing issues, potentially reshaping access to medications for millions of Medicare recipients.

1 of 2

Story summary

U.S. President Donald Trump announced a deal with Eli Lilly and Novo Nordisk to cut GLP-1 prices for Medicare and Medicaid recipients, effective January 2026.
Co-pays will be capped at $50 per month, with cash prices as low as $299.
The agreement includes tariff relief and fast-track regulatory vouchers for future drugs.
Novo Nordisk plans a $10 billion U.S. investment, and GLP-1 coverage expands to prediabetes and heart patients.

1 / 2